Arbutus Biopharma Corporation ABUS Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's unrealized losses on investments (before tax)?
- Arbutus Biopharma Corporation (ABUS) reported unrealized losses on investments (before tax) of $23K in Q1 2026.
- How has Arbutus Biopharma Corporation's unrealized losses on investments (before tax) changed year-over-year?
- Arbutus Biopharma Corporation's unrealized losses on investments (before tax) increased by 360.0% year-over-year, from $5K to $23K.
- What is the long-term trend for Arbutus Biopharma Corporation's unrealized losses on investments (before tax)?
- Over 2 years (2020 to 2025), Arbutus Biopharma Corporation's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $1K to $0.